Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber

British Journal of Pharmacology

Volumn 117, Issue 8, 1996, Pages 1730-1734

  Lampen, Alfonso ^a   Christians, Uwe ^a   Gonschior, Ann Katrin ^a   Bader, Augustinus ^a   Hackbarth, Ingelore ^a   Von Engelhardt, Wolfgang ^b   Sewing, Karl Friedrich ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Drug metabolism; Gut mucosa; Intestinal mucosa; Pre hepatic metabolism; Tacrolimus; Ussing chamber

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; MACROLIDE; TACROLIMUS; TROLEANDOMYCIN;

ANIMAL TISSUE; ARTICLE; COLON; CONCENTRATION RESPONSE; DRUG METABOLISM; DRUG TRANSPORT; DUODENUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; ILEUM; INTESTINE MUCOSA; JEJUNUM; MASS SPECTROMETRY; MICROSOME; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH; SWINE;

EID: 0029930064     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15346.x     Document Type: Article

References (33)

1. BACK, D.J. & ROGERS, S.M. (1987). First pass metabolism by the gastrointestinal mucosa. Aliment. Pharmacol. Ther., 1, 339-357.
2. CHANG, T., GONZALEZ, F.J. & WAXMAN, D.J. (1994). Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochrome P450. Arch. Biochem. Biophys., 311, 437-442.
3. CHRISTIANS, U., BRAUN, F., SCHMIDT, M., KOSIAN, N., SCHIEBEL, H.M., ERNST, L., WINKLER, M., KRUSE, C., LINCK, A. & SEWING, K.F. (1992a). Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients. Clin. Chem., 38, 2025-2032.
4. CHRISTIANS, U., KRUSE, C., KOWNATZKI, R., SCHIEBEL, H.M., SCHWINZER, R., SATTLER, M., SCHOTTMANN, R., LINCK, A., ALMEIDA, V.M.F., BRAUN, F. & SEWING, K.F. (1991). Measurement of FK506 by HPLC and isolation and characterization of its metabolites. Transplant. Proc., 23, 940-941.
5. CHRISTIANS, U., SATTLER, M., SCHIEBEL, H.M., KRUSE, C., RADEKE, H.H., LINCK, A. & SEWING, K.F. (1992b). Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab. Dispos., 20, 186-191.
6. ENGELHARDT, W., BURMESTER, M., HANSEN, K., BECKER, G. & RECHKEMMER, G. (1993). Effects of amiloride and ouabain on short-chain fatty acid transport in guinea-pig large intestine. J. Physiol., 460, 455-466.
7. EUROPEAN FK506 MULTICENTRE LIVER STUDY GROUP. (1994). Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet, 344, 423-428.
8. GONSCHIOR, A.K., CHRISTIANS, U., BRAUN, F., WINKLER, M., LINCK, A., BAUMANN, J. & SEWING, K.F. (1994). Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle immunoassay (MEIA). Br. J. Clin. Pharmacol., 38, 567-571.
9. HEBERT, M.F., ROBERTS, J.P., PRUEKSARITANONT, T. & BENET, L.Z. (1992). Bioavailability of cyclosporine with rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther., 52, 453-457.
10. IWASAKI, K., SHIRAGA, T., MATSUDA, K., NAGASE, Y., TOKUMA, T., HATA, T., FUJII, Y., SAKUMA, S., FUJITSU, T., FUJIKAWA, A., SHIMATANI, K., SATO, A. & FUJIOKA, M. (1995). Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug. Metab. Dispos., 23, 28-34.
11. IWASAKI, K., SHIRAGA, T., NAGASE, K., TOZUKA, Z., NODA, K., SAKUMA, S., FUJITSU, T., SHIMATANI, K., SATO, A. & FUJIOKA, M. (1993). Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab. Dispos., 21, 971-977.
12. KARANAM, B.V., VINCENT, S.H. & CHIU, S.H.L. (1994). FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4. Drug Metab. Dispos., 22, 811-814.
13. KOLARS, J.C. LOWN, K.S., SCHMIEDLIN-REN, P., GHOSH, M., FANG, C., WRIGHTON, S.A., MERION, R.M. & WATKINS P.B. (1994). CYP3A gene expression in human gut epithelium. Pharmacogenetics, 4, 247-259.
14. KOLARS, J.C., STETSON, P.L., RUSH, B.D., RUWART, M.J., SCHMIEDLIN-REN, P., DUELL, E.A., VOORHEES, J.J. & WATKINS, P.B. (1992). Cyclosporin A metabolism by P450IIIA in rat enterocytes - another determinant of oral bioavailability? Transplantation, 53, 596-602.
15. KROEMER, H.K., GAUTIER, J.C., BEAUNE, P., HENDERSON, C., WOLF, C.R. & EICHELBAUM, M. (1993). Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn-Schmied. Arch. Pharmacol., 348, 332-337.
16. LHOËST, G.J., MATON, N. & LATINNE, D. (1994). 15-Desmethyl and 15,31-Desmethyl FK-506 from human liver microsomes: isolation, identification (by fast bombardment mass spectrometry and NMR), and evaluation of in vitro immunosuppressive activity. Clin. Chem., 40, 740-744.
17. PETERS, D.H., FITTON, A., PLOSKER, G.L. & FAULDS, D. (1993). Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs, 46, 746-794.
18. PINKUS, L.M. (1981). Separation and use of enterocytes. In Methods in Enzymology ed. Jakoby, W.B., Vol. 77, pp. 154-162. New York: Academic Press.
19. PORTEOUS, J.W., FURNEAUX, H.M., PEARSON, C.K., LAKE, C.M., MORISON, A. (1979). Poly (adenosine diphosphate ribose) synthetase activity in nuclei of dividing but differentiating intestinal epithelial cells. Biochem. J., 180, 455-463.
20. ROGERS, S.M., BACK, D.J. & ORME, M. (1987). Intestinal metabolism of ethinylestradiol and paracetamol in in vitro studies using Ussing chambers. Br. J. Clin. Pharmacol., 23, 727-734.
21. SATTLER, M., GUENGERICH, F.P., YUN, C.Y., CHRISTIANS, U. & SEWING, K.Fr. (1992). Cytochrome P-4503A4 is responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos., 20, 753-761.
22. SCHRÖDER, B., KAUNE, R. & HARMEYER, J. (1991). Effects of calcitriol on stimulation of ion transport in pig jejunal mucosa. J. Physiol., 433, 451-465.
23. SCHÜLER, W., CHRISTIANS, U., SCHMIEDER, P., SCHIEBEL, H.M., HOLZE, I., SEWING, K.F. & KESSLER, H. (1993). Structural identification of 13-demethyl-FK506 and its isomers generated by in vitro metabolism of FK506 using human liver microsomes. Helv. Chim. Acta, 76, 2288-2302.
24. SHIRAGA, T., MATSUDA, M., NAGASE, K , IWASAKI, K., NODA, K., YAMAZAKE, H., SHIMADA, T. & FUNAE, Y. (1993). Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem. Pharmacol., 47, 727-735.
25. TIJA, J.F., WEBBER, I.R. & BACK, D.J. (1991). Cyclosporin metabolism by gastrointestinal mucosa. Br. J. Clin. Pharmacol., 31, 344-346.
26. THE U.S. MULTICENTER FK 506 STUDY GROUP. (1994). A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N. Engl. J. Med., 331, 1110-1115.
27. USSING, H.H. (1949). The distinction by means of tracers between active transport and diffusion. The transfer of iodide across the isolated frog skin. Acta Physiol. Scand. 19, 43-56.
28. USSING, H.H. & ZERAHN, K. (1951). Active transport of sodium as source of electric current in the short-circuited isolated frog skin. Acta Physiol. Scand., 23, 110-127.
29. VINCENT, S.H., KARAMAN, B.V., PAINTER, S.K. & S-H.L. CHIU. (1992). In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch. Biochem. Biophys., 294, 454-460.
30. WALLEMACQ, P.E. & REDING, R. (1993). FK 506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical and analytical aspects. Clin. Chem., 39, 2219-2228.
31. WATKINS, P.B. (1990). The cytochromes P-450. Gastroenterol. Int., 3, 184-188.
32. WATKINS, P.B., WRIGHTON, S.A., SCHUETZ, E.G., MOLOWA, D.T. & GUZELIAN, P.S. (1987). Identification of glucocorticoid-inducible cytochrome P-450 in the intestinal mucosa of rats and man. J. Clin. Invest., 80, 1029-1036.
33. YUN, C.H., LEE, H.S., LEF, H., RHO, J.K., JEONG, H.G. & GUENGERICH, F.P. (1995). Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug. Metab. Dispos., 23, 285-289.